

Quantity Limit

Antiviral for Post-Exposure Prophylaxis of COVID-19

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Xocova	ensitrelvir

Indications

FDA-approved Indications

Xocova is indicated for post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents 12 years of age and older following contact with an individual who has COVID-19.

Initial Limit Quantity

This drug is for short-term acute use.

Drug	Limit
Xocova (ensitrelvir) 125 mg tablet	7 tablets / 30 days

References

1. Xocova [package insert]. Florham Park, NJ: Shionogi Inc.; May 2026.

Reference number(s)
7513-H

2. Lexicomp Online, Lexi-Drugs Online. Waltham, MA: UpToDate, Inc.; 2026. <https://online.lexi.com>. Accessed June 10, 2026.
3. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 06/10/2026).